IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 45 filers reported holding IMPEL NEUROPHARMA INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 1.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,239 | +22434.1% | 21,485 | -26.9% | 0.00% | – |
Q1 2023 | $41 | -100.0% | 29,401 | -7.7% | 0.00% | – |
Q3 2022 | $155,000 | -88.5% | 31,842 | -77.9% | 0.00% | -100.0% |
Q2 2022 | $1,344,000 | +950.0% | 144,207 | +872.6% | 0.00% | – |
Q4 2021 | $128,000 | +1.6% | 14,827 | +43.8% | 0.00% | – |
Q3 2021 | $126,000 | – | 10,314 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
NVP Associates, LLC | 3,077,198 | $11,539,493 | 11.26% |
Vivo Capital, LLC | 2,884,789 | $43,272 | 4.98% |
venBio Partners LLC | 2,759,791 | $10,349,216 | 3.21% |
5AM Venture Management, LLC | 2,884,791 | $10,817,966 | 2.91% |
LASRY MARC | 408,329 | $1,531,234 | 2.38% |
DCF Advisers, LLC | 325,825 | $1,221,844 | 0.83% |
Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $15,509,891 | 0.52% |
EPIQ PARTNERS, LLC | 18,646 | $69,923 | 0.05% |
J. Goldman & Co LP | 200,219 | $750,821 | 0.04% |
MCDONALD PARTNERS LLC | 11,700 | $43,875 | 0.02% |